Baringa Says £1,200 GLP-1 Cost Only Pays Off Above £97,500, Fueling Inequality
Updated
Updated · The Guardian · Aug 15
Baringa Says £1,200 GLP-1 Cost Only Pays Off Above £97,500, Fueling Inequality
1 articles · Updated · The Guardian · Aug 15
Summary
Nearly £97,500 in post-tax discretionary income is needed before annual grocery savings match the roughly £1,200 cost of GLP-1 weight-loss drugs, Baringa said; at £39,000, users save only £481 on food.
Baringa called that gap a “regressive tax on being thin,” arguing most private-pay users spend more on the drugs than they recoup, with extra costs for vitamins and hair-care products linked to side effects.
Industry groups say limited NHS eligibility shields some patients from those costs, but many people can access treatment only through private prescriptions, raising the risk that affordability widens health inequalities.
About 5% of British adults—nearly 3 million people—are currently using weight-loss medication, PwC estimates, with 20% of users in households earning above £100,000 versus 6% below £20,000.
England has 14.3 million adults living with obesity, and pharmacists say cost-driven stop-start use can lead to weight regain, debt pressure and stronger demand for cheaper next-generation GLP-1 options.
Could the soaring cost of new weight-loss pills create a permanent biological health divide between the wealthy and the working class?
Are pharmaceutical pricing models secretly relying on a lucrative cycle of patients starting, stopping, and desperately returning to weight-loss drugs?
What happens to public healthcare systems when millions are forced to abandon expensive private weight-loss treatments and rapidly regain weight?